Replimune's RP1 BLA Accepted by FDA for Review
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2025
0mins
Replimune Group Inc's stock rose by 5.03% as it crossed above the 5-day SMA, reflecting positive investor sentiment following the FDA's acceptance of its Biologics License Application (BLA) for RP1.
The FDA has accepted Replimune's BLA for RP1, which is intended for advanced melanoma treatment in combination with nivolumab. This significant advancement is based on data from the IGNYTE clinical trial, showcasing RP1's potential to enhance cancer treatment options. The FDA is expected to make a decision by August 2, 2026, indicating the urgency for effective melanoma therapies amid rising case numbers in the U.S.
This development positions Replimune favorably in the competitive oncology market, as the acceptance of the BLA could lead to new treatment options for patients and potentially increase the company's market share in the melanoma treatment landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REPL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REPL
Wall Street analysts forecast REPL stock price to fall
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 11.470
Low
3.00
Averages
11.43
High
18.00
Current: 11.470
Low
3.00
Averages
11.43
High
18.00
About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Rally as Tech Leads Gains Amid Strong Economic Signals
- Tech Stocks Lead Market: The S&P 500 rose by 0.34% and the Nasdaq 100 by 0.97%, reflecting investor optimism ahead of a strong earnings season, particularly driven by an investment boom in artificial intelligence.
- Strong Labor Market: May JOLTS job openings unexpectedly increased by 9,000 to a two-year high of 7.594 million, indicating a stronger labor market than anticipated, which may influence the Fed's monetary policy direction.
- Positive Global Economic Signals: China's June manufacturing PMI rose to 50.3, exceeding expectations, indicating signs of economic recovery that support global growth prospects and further bolster market confidence.
- Optimistic Earnings Outlook: Bloomberg Intelligence forecasts a 23% increase in Q2 earnings, close to Q1's 30% growth, primarily driven by AI infrastructure stocks expected to contribute nearly 60% of S&P 500 earnings growth.
See More
U.S. Stocks Edge Up, Led by Technology Sector
- Tech Sector Drives Market: The S&P 500 and Nasdaq 100 indices rose by 0.08% and 0.50%, respectively, reaching one-week highs, reflecting investor optimism ahead of a strong earnings season, particularly driven by an investment boom in artificial intelligence.
- Economic Data Beats Expectations: The April S&P CoreLogic Case-Shiller 20-City Home Price Index increased by 1.14% year-over-year, surpassing the expected 0.90%, indicating resilience in the housing market that could further support stock performance.
- China's Economic Recovery: China's June manufacturing PMI rose to 50.3, exceeding expectations of 50.1, signaling improved global growth prospects and boosting market confidence in economic recovery.
- Optimistic Earnings Outlook: Bloomberg Intelligence forecasts a 23% increase in Q2 earnings, close to Q1's 30% growth, indicating that AI infrastructure stocks are expected to contribute nearly 60% of earnings growth, further enhancing market sentiment.
See More
Replimune Group Reports $313.94 Million Annual Loss
- Annual Loss Overview: Replimune Group reported a full-year loss of $313.94 million for 2023, compared to a loss of $247.30 million last year, indicating ongoing financial pressure that could impact future fundraising capabilities.
- Earnings Per Share Analysis: The earnings per share (EPS) stood at -$3.38, an increase from -$3.07 the previous year, reflecting challenges in profitability that may lead to decreased investor confidence.
- Financial Comparison: The loss increased by approximately 24.5% year-over-year, suggesting difficulties in cost control and revenue growth, which may necessitate a reassessment of the company's business strategy to improve financial health.
- Market Reaction Expectations: Given the continued losses, the market is expected to adopt a cautious stance towards Replimune's future performance, potentially affecting its stock price and long-term investor confidence.
See More
Replimune Reports FY GAAP EPS Miss, Cash Burn Concerns
- Disappointing Earnings: Replimune's reported FY GAAP EPS of -$3.38 misses expectations by $0.02, indicating ongoing challenges in profitability that could negatively impact investor confidence.
- Cash Flow Decline: As of March 31, 2026, the company's cash and short-term investments totaled $268.9 million, down significantly from $483.8 million at the end of FY 2025, reflecting increased cash burn related to advancing clinical development plans, which may affect future operational flexibility.
- Funding Strategy: Based on its current operating plan, Replimune believes that existing cash and short-term investments will fund operations into Q1 2027, including scaling up for potential RP1 commercialization in skin cancers and general corporate purposes, demonstrating cautious optimism about future growth.
- Uncertain FDA Approval Outlook: Despite challenges in advancing RP1 through the FDA approval process, the company aims to support its clinical trials and commercialization plans with existing funds; however, the outcome of the FDA review will directly impact market performance and investor sentiment.
See More
High Options Trading Volume for Qualcomm and Replimune
- Qualcomm Options Volume: Qualcomm (QCOM) saw an options trading volume of 126,866 contracts today, representing approximately 12.7 million shares, which is about 57.5% of its average daily trading volume of 22 million shares over the past month, indicating strong market interest in its future performance.
- Bullish Call Options: Notably, the $200 strike call option expiring on June 26, 2026, has seen 6,196 contracts traded today, representing around 619,600 underlying shares, suggesting that investors are increasingly optimistic about Qualcomm's stock price appreciation.
- Replimune Options Activity: Replimune (REPL) has recorded an options trading volume of 35,327 contracts today, equivalent to approximately 3.5 million shares, which accounts for about 56.1% of its average daily trading volume of 6.3 million shares over the past month, reflecting investor confidence in its growth potential.
- Call Options Interest: Particularly, the $15 strike call option expiring on August 21, 2026, has seen a trading volume of 5,896 contracts today, representing approximately 589,600 shares, indicating a bullish sentiment among market participants regarding Replimune's stock price trajectory.
See More
Replimmune's RP-1 BLA Accepted by FDA for Melanoma Treatment
- FDA Application Acceptance: Replimmune Group Inc. announced that its biological license application (BLA) for RP-1 in combination with nivolumab for advanced melanoma has been accepted by the FDA, marking a significant advancement in cancer treatment.
- Melanoma Statistics: Melanoma is the fifth most common cancer globally, with over 112,000 new cases diagnosed in the U.S. this year and approximately 8,500 deaths annually, highlighting the urgent need for effective treatment options.
- Drug Background: RP-1 is Replimmune's lead drug candidate, utilizing an attenuated herpes simplex virus linked to a cell-stimulating factor to enhance the immunogenicity of cancer cells, previously showing positive results in the Phase 3 IGNYTE trial.
- Review Process: This BLA review marks the company's third submission, with the FDA expected to deliver a class-1 response by August 2, 2026, reflecting the ongoing efforts and challenges faced in the drug development process.
See More
US Stocks Rally as Tech Leads Gains Amid Strong Economic Signals
- Tech Stocks Lead Market: The S&P 500 rose by 0.34% and the Nasdaq 100 by 0.97%, reflecting investor optimism ahead of a strong earnings season, particularly driven by an investment boom in artificial intelligence.
- Strong Labor Market: May JOLTS job openings unexpectedly increased by 9,000 to a two-year high of 7.594 million, indicating a stronger labor market than anticipated, which may influence the Fed's monetary policy direction.
- Positive Global Economic Signals: China's June manufacturing PMI rose to 50.3, exceeding expectations, indicating signs of economic recovery that support global growth prospects and further bolster market confidence.
- Optimistic Earnings Outlook: Bloomberg Intelligence forecasts a 23% increase in Q2 earnings, close to Q1's 30% growth, primarily driven by AI infrastructure stocks expected to contribute nearly 60% of S&P 500 earnings growth.
See More
U.S. Stocks Edge Up, Led by Technology Sector
- Tech Sector Drives Market: The S&P 500 and Nasdaq 100 indices rose by 0.08% and 0.50%, respectively, reaching one-week highs, reflecting investor optimism ahead of a strong earnings season, particularly driven by an investment boom in artificial intelligence.
- Economic Data Beats Expectations: The April S&P CoreLogic Case-Shiller 20-City Home Price Index increased by 1.14% year-over-year, surpassing the expected 0.90%, indicating resilience in the housing market that could further support stock performance.
- China's Economic Recovery: China's June manufacturing PMI rose to 50.3, exceeding expectations of 50.1, signaling improved global growth prospects and boosting market confidence in economic recovery.
- Optimistic Earnings Outlook: Bloomberg Intelligence forecasts a 23% increase in Q2 earnings, close to Q1's 30% growth, indicating that AI infrastructure stocks are expected to contribute nearly 60% of earnings growth, further enhancing market sentiment.
See More
Replimune Group Reports $313.94 Million Annual Loss
- Annual Loss Overview: Replimune Group reported a full-year loss of $313.94 million for 2023, compared to a loss of $247.30 million last year, indicating ongoing financial pressure that could impact future fundraising capabilities.
- Earnings Per Share Analysis: The earnings per share (EPS) stood at -$3.38, an increase from -$3.07 the previous year, reflecting challenges in profitability that may lead to decreased investor confidence.
- Financial Comparison: The loss increased by approximately 24.5% year-over-year, suggesting difficulties in cost control and revenue growth, which may necessitate a reassessment of the company's business strategy to improve financial health.
- Market Reaction Expectations: Given the continued losses, the market is expected to adopt a cautious stance towards Replimune's future performance, potentially affecting its stock price and long-term investor confidence.
See More
Replimune Reports FY GAAP EPS Miss, Cash Burn Concerns
- Disappointing Earnings: Replimune's reported FY GAAP EPS of -$3.38 misses expectations by $0.02, indicating ongoing challenges in profitability that could negatively impact investor confidence.
- Cash Flow Decline: As of March 31, 2026, the company's cash and short-term investments totaled $268.9 million, down significantly from $483.8 million at the end of FY 2025, reflecting increased cash burn related to advancing clinical development plans, which may affect future operational flexibility.
- Funding Strategy: Based on its current operating plan, Replimune believes that existing cash and short-term investments will fund operations into Q1 2027, including scaling up for potential RP1 commercialization in skin cancers and general corporate purposes, demonstrating cautious optimism about future growth.
- Uncertain FDA Approval Outlook: Despite challenges in advancing RP1 through the FDA approval process, the company aims to support its clinical trials and commercialization plans with existing funds; however, the outcome of the FDA review will directly impact market performance and investor sentiment.
See More
High Options Trading Volume for Qualcomm and Replimune
- Qualcomm Options Volume: Qualcomm (QCOM) saw an options trading volume of 126,866 contracts today, representing approximately 12.7 million shares, which is about 57.5% of its average daily trading volume of 22 million shares over the past month, indicating strong market interest in its future performance.
- Bullish Call Options: Notably, the $200 strike call option expiring on June 26, 2026, has seen 6,196 contracts traded today, representing around 619,600 underlying shares, suggesting that investors are increasingly optimistic about Qualcomm's stock price appreciation.
- Replimune Options Activity: Replimune (REPL) has recorded an options trading volume of 35,327 contracts today, equivalent to approximately 3.5 million shares, which accounts for about 56.1% of its average daily trading volume of 6.3 million shares over the past month, reflecting investor confidence in its growth potential.
- Call Options Interest: Particularly, the $15 strike call option expiring on August 21, 2026, has seen a trading volume of 5,896 contracts today, representing approximately 589,600 shares, indicating a bullish sentiment among market participants regarding Replimune's stock price trajectory.
See More
Replimmune's RP-1 BLA Accepted by FDA for Melanoma Treatment
- FDA Application Acceptance: Replimmune Group Inc. announced that its biological license application (BLA) for RP-1 in combination with nivolumab for advanced melanoma has been accepted by the FDA, marking a significant advancement in cancer treatment.
- Melanoma Statistics: Melanoma is the fifth most common cancer globally, with over 112,000 new cases diagnosed in the U.S. this year and approximately 8,500 deaths annually, highlighting the urgent need for effective treatment options.
- Drug Background: RP-1 is Replimmune's lead drug candidate, utilizing an attenuated herpes simplex virus linked to a cell-stimulating factor to enhance the immunogenicity of cancer cells, previously showing positive results in the Phase 3 IGNYTE trial.
- Review Process: This BLA review marks the company's third submission, with the FDA expected to deliver a class-1 response by August 2, 2026, reflecting the ongoing efforts and challenges faced in the drug development process.
See More
